Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 11, 2020
- Accepted in final form September 23, 2020
- First Published November 17, 2020.
Author Disclosures
- Sinah Engel, MD*,
- Valérie Jolivel, PhD*,
- Stefan H.-P. Kraus, PhD,
- Morad Zayoud, MD,
- Karolina Rosenfeld,
- Hayrettin Tumani, MD,
- Roberto Furlan, MD, PhD,
- Florian C. Kurschus, PhD,
- Ari Waisman, PhD and
- Felix Luessi, MD
- Sinah Engel, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Valérie Jolivel, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan H.-P. Kraus, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Morad Zayoud, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Karolina Rosenfeld,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hayrettin Tumani, MD,
Alexion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, Teva
NONE
Speaker honoraria from Alexion, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi
BMBF
University of Ulm
DMSG
NONE
NONE
NONE
NONE
NONE
NONE
- Roberto Furlan, MD, PhD,
(1) Novartis
NONE
speaker honoraria from Merck Serono, Novartis, Biogen, and Roche
Academic Editor of PLoS One since 2012
(1) CSF microvesicles are a marker of microglial activation
NONE
NONE
NONE
NONE
NONE
NONE
(1) EMD Serono
(1)Italian Ministry for Health (2) Italian Ministry of University and Research
NONE
Italian Foundation for Multiple Sclerosis (FISM)
NONE
NONE
NONE
NONE
NONE
NONE
- Florian C. Kurschus, PhD,
NONE
NONE
1) Novartis, funding for travel and meeting attendance of the "IL-17 Summit 2019"
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) DFG, SFB/TR-128 TPA3 to F.C.K.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ari Waisman, PhD and
Served on scientific advisory board of Novartis on the role of IL-17 in cardiovascular diseases
NONE
NONE
Editor in Chief of the Journal of Molecular Medicine 2017-Date, Board member of Cellular Immunology 2016-Date,Board Member of Acta Neuropathologica 2014-Date Associate Editor PLoS One 2014-Date
NONE
NONE
Receive honoraria from Springer/Nature as Editor in Chief
NONE
NONE
NONE
NONE
Received honoraria from Novartis as member of advisory board (see up for details)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Felix Luessi, MD
advisory board member for Roche Pharma
NONE
travel funding from Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (S.E., V.J., S.H.-P.K., K.R., F.L.), Focus Program Translational Neuroscience (FTN), University Medical Center of the Johannes Gutenberg University of Mainz, Germany; Biopathology of Myelin (V.J.), Neuroprotection and Therapeutic Strategy, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), University of Strasbourg, France; Institute for Molecular Medicine (M.Z., F.C.K., A.W.), University Medical Centre of the Johannes Gutenberg University of Mainz, Germany; Sheba Cancer Research Center (M.Z.), Chaim Sheba Academic Medical Center, Ramat Gan, Israel; Department of Neurology (H.T.), University of Ulm, Germany and Specialty Clinic of Neurology Dietenbronn, Schwendi, Germany; Clinical Neuroimmunology Unit (R.F.), San Raffaele Scientific Institute, Milan, Italy; and Department of Dermatology (F.C.K.), Heidelberg University Hospital, Heidelberg, Germany.
- Correspondence
Dr. Luessi luessi{at}uni-mainz.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAECyril Laurent, Gabrielle Deblois, Marie-Laure Clénet et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2020 -
Article
Myeloid cells as target of fingolimod action in multiple sclerosisMarco Di Dario, Emanuela Colombo, Chiara Govi et al.Neurology - Neuroimmunology Neuroinflammation, November 04, 2015 -
Article
Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progressionMichel Varrin-Doyer, Kara L. Pekarek, Collin M. Spencer et al.Neurology: Neuroimmunology & Neuroinflammation, September 21, 2016 -
Article
Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAENiannian Ji, Andra Kovalovsky, Günter Fingerle-Rowson et al.Neurology - Neuroimmunology Neuroinflammation, August 06, 2015